CStone Reports PD-L1 Meets Endpoint in Phase III NSCLC Trial
May 28, 2021 at 06:57 AM EDT
Suzhou CStone Pharma reported that its anti-PD-L1 mAb met its primary endpoint in a Phase III trial in patients with stage III NSCLC. Data from a planned interim analysis showed sugemalimab patients experienced a statistically significant and clinically meaningful improvement in progression-free survival. CStone plans to submit an NDA for China approval of sugemalimab in stage III NSCLC. The company will collaborate with Pfizer to commercialize sugemalimab in mainland China , and it out-licensed ex-China rights for the candidate to EQRx. More details.... Stock Symbol: (HK: 2616) Share this with colleagues: // //
